Evidence map›Paper›PMID 34781741›Full record

ArticlemBio2021

HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy.

F Harrison Omondi, Hanwei Sudderuddin, Aniqa Shahid, Natalie N Kinloch, Bradley R Jones, Rachel L Miller, Olivia Tsai, Daniel MacMillan, Alicja Trocha, Mark A Brockman and 5 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Dolutegravir based therapy showed CD4Scientific reports · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

F Harrison Omondi *Faculty of Health Sciences, Simon Fraser Universitygrid.61971.38, Burnaby, British Columbia, Canada.ORCID 0000-0003-0940-7512
Hanwei Sudderuddin *British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Aniqa ShahidFaculty of Health Sciences, Simon Fraser Universitygrid.61971.38, Burnaby, British Columbia, Canada.
Natalie N KinlochFaculty of Health Sciences, Simon Fraser Universitygrid.61971.38, Burnaby, British Columbia, Canada.
Bradley R JonesBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Rachel L MillerBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Olivia TsaiFaculty of Health Sciences, Simon Fraser Universitygrid.61971.38, Burnaby, British Columbia, Canada.
Daniel MacMillanBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Alicja TrochaRagon Institute of MGH, MIT and Harvardgrid.461656.6, Cambridge, Massachusetts, USA.
Mark A BrockmanFaculty of Health Sciences, Simon Fraser Universitygrid.61971.38, Burnaby, British Columbia, Canada.ORCID 0000-0001-6432-1426
Chanson J BrummeBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Jeffrey B JoyBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Richard LiangBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Bruce D WalkerRagon Institute of MGH, MIT and Harvardgrid.461656.6, Cambridge, Massachusetts, USA.
Zabrina L BrummeFaculty of Health Sciences, Simon Fraser Universitygrid.61971.38, Burnaby, British Columbia, Canada.ORCID 0000-0002-8157-1037
Simon Fraser University · CAUniversity of British Columbia · CAAIDS Vancouver · CARagon Institute of MGH, MIT and Harvard · US

Funding

REACH: Research Enterprise to Advance a Cure for HIVUM1AI164565 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Marina Caskey, R. Brad Jones · 2021 to 2026
$32.9M
CIHR PJT-159625NIAID NIH HHS UM1 AI164565Wellcome Trust
6 · The paper itself

Abstract

Curing HIV will require eliminating the reservoir of integrated, replication-competent proviruses that persist despite antiretroviral therapy (ART). Understanding the burden, genetic diversity, and longevity of persisting proviruses in diverse individuals with HIV is critical to this goal, but these characteristics remain understudied in some groups. Among them are viremic controllers-individuals who naturally suppress HIV to low levels but for whom therapy is nevertheless recommended. We reconstructed within-host HIV evolutionary histories from longitudinal single-genome amplified viral sequences in four viremic controllers who eventually initiated ART and used this information to characterize the age and diversity of proviruses persisting on therapy. We further leveraged these within-host proviral age distributions to estimate rates of proviral turnover prior to ART. This is an important yet understudied metric, since pre-ART proviral turnover dictates reservoir composition at ART initiation (and thereafter), which is when curative interventions, once developed, would be administered. Despite natural viremic control, all participants displayed significant within-host HIV evolution pretherapy, where overall on-ART proviral burden and diversity broadly reflected the extent of viral replication and diversity pre-ART. Consistent with recent studies of noncontrollers, the proviral pools of two participants were skewed toward sequences that integrated near ART initiation, suggesting dynamic proviral turnover during untreated infection. In contrast, proviruses recovered from the other two participants dated to time points that were more evenly spread throughout infection, suggesting slow or negligible proviral decay following deposition. HIV cure strategies will need to overcome within-host proviral diversity, even in individuals who naturally controlled HIV replication before therapy.

Indexed as

AgedAnti-HIV AgentsCohort StudiesElite ControllersEvolution, MolecularGenetic VariationGenome, ViralHIV-1HIV InfectionsHumansLongitudinal StudiesMaleMiddle AgedPhylogenyProvirusesViral LoadAnti-HIV Agentsgenetic diversityhuman immunodeficiency virusproviral burden and dynamicsproviral half-lifeviremic controllers

Identifiers

PMID34781741
PMCPMC8693448
OpenAlexW3212714974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.